The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

A Pre-Conference Program; additional registration is required.

Wednesday, Nov. 10, 2021*
2–6 p.m. EST

*Dates and times subject to change. 


Program Purpose

It has been a decade since the first approval of an immune checkpoint inhibitor. In the ten years since, the field of cancer immunotherapy has seen unprecedented growth. In order to further improve patient outcomes, cancer immunotherapy approaches are constantly evolving. This program will discuss three key areas for the future of cancer immunotherapy: immunity beyond T cells, the application of CAR T therapy in solid tumors, and novel immunotherapy combinations. Addressing these key areas will help the next ten years of immunotherapy be as successful as the last.

 

Program Organizers

  • Kald Abdallah, MD, PhD – Bristol Myers Squibb
  • Mary Margaret Huizinga, MD, MPH, FACP – Novartis Pharmaceuticals
  • Francesco M. Marincola, MD – Kite, A Gilead Company
  • Giovanni Melillo, MD – AstraZeneca
  • Zhen Su, MD, PhD – Marengo Therapeutics 


Target Audience

The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.


Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Outline the role of immune cells other than T cells in anti-cancer immunity
  • Summarize the state of CAR T application in solid tumors and future directions for this field
  • Discuss the rational combination of immunotherapies with other anti-cancer modalities to improve patient outcomes

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations is supported in part by grants from Bristol Myers Squibb and Genentech, Inc.


Program Schedule

Session I: Immunity Beyond T cells
2–3:20 p.m. EST

2 p.m.

Welcome: Unleashing Curiousity, Courage and Conviction for The Next Wave of Immunotherapy
Zhen Su, MD, MBA - Marengo Therapeutics

2:10 p.m. Beyond the Horizon. How Targeting Myeloid cells can Revolutionize Cancer   Immunotherapy
Dmitry I. Gabrilovich, MD, PhD - AstraZeneca

2:30 p.m. Leveraging B-cell Immunity to Promote PD-1 blockade Effectiveness in Glioblastoma
David Hou - Northwestern University

2:40 p.m. A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence
Luxuan Buren, PhD - Nkarta Therapeutics

2:50 p.m. Panel Discussion
Moderator:
Francesco M. Marincola, MD - Kite, A Gilead Company
Panelists:
Dmitry I. Gabrilovich, MD, PhD - AstraZeneca
                  Katy Rezvani, MD, PhD - MD Anderson Cancer Center

Session II: CAR T and other Cell Therapies in Solid Tumors
3:204:30 p.m. EST

3:20 p.m. Equipping CAR T for Solid Tumors: Challenges and Opportunities 
Carl H. June, MD - University of Pennsylvania 

3:40 p.m. Secretion of Matrix Metallopeptidase 8 Promotes Tumor Infiltration and Antitumor Activity of CAR T cells
Irfan N. Bandey, PhD - University of Houston
 
3:50 p.m. AlloCAR TTM Cells Built for Enhanced Expansion, Persistence, and the Ability to Overcome the Solid Tumor Microenvironment
Barbra J. Sasu, PhD - Allogene Therapeutics

4:00 p.m. Debate/Panel Discussion
Moderator: Mary Margaret Huizinga, MD, MPH, FACP - Novartis Pharmaceuticals
Panelists: Carl H. June, MD - University of Pennsylvania
                  Marcela V. Maus, MD, PhD - Massachusetts General Hospital
4:30 p.m. Break

Session III: Novel Combinations
4:456:00 p.m. EST

4:45 p.m. The Evolving Landscape of Immunotherapy Combinations
Jonathan Cheng, MD - Bristol Myers Squibb

5:05 p.m. Beyond T cells and Bispecific Antibodies for Solid Tumors: Odyssey of Bispecific Antibody (BiAb) Armed Activated T cells (BATs)
Lawrence G. Lum, MD, DSc - University of Virginia

5:15 p.m. INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma
David A. Reardon, MD - Dana-Farber Cancer Institute

5:25 p.m. Panel Discussion
Moderator: Giovanni Melillo, MD - AstraZeneca
Panelists: Jonathan Cheng, MD - Bristol Myers Squibb
                  Sandra Demaria, MD - Weill Cornell Medicine
                  
5:55 p.m. Closing Remarks
Kald Abdallah, MD, PhD - Bristol Myers Squibb

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Abstracts

Abstracts in this program will discuss one of the following three key areas: immunity beyond T cells, the application of CAR T therapy in solid tumors, or novel immunotherapy combinations. Abstract presentations will be approximately 10 minutes in length. Call for Abstracts for this program will open at the end of June, with a deadline of 5 p.m. PDT on Aug. 19, 2021. For more information, please view the Abstract Guide.


Important Abstract Dates

Date Details

June 30, 2021

Abstract submission site opens for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Aug. 19, 2021

Abstract submission site closes at 5 p.m. PDT for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Sept. 24, 2021

Abstract notifications sent for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Oct. 1, 2021

Accepted abstract confirmations due and deadline for withdrawals and changes for The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations

Oct. 1, 2021

Presenter Information and Registration for Accepted Abstracts Due

Oct. 14, 2021

Presentation Slides and Recording Permission for Accepted Abstract Presenters Due

Nov. 10, 2021

The Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Pre-Conference Program

Nov. 10-14, 2021   36th Annual Meeting & Pre-Conference Programs

Reasons to Submit Your Abstract to the Evolution of Immunotherapy: An Exploration of Immunity Beyond T cells, CAR T in Solid Tumors and Novel Combinations Program
  • Multiple oral presentation opportunities available
  • The opportunity to present and discuss your research with luminaries in the immunotherapy field
  • Addressing these key topics/areas will continue to help the field of immunotherapy in the coming years

     

    SITC Related Resources

    SITC offers a variety of resources about immunology, immunotherapy and cellular therapy. Explore the pages below to learn more.
    SITC_Primer_2019.jpg
    SITC_2019_Primer_2.jpg